A 3-month, Randomized, Placebo-controlled, Double-masked, Multi-center Study to Evaluate the Safety and Efficacy of Topical Ocular UNR844-Cl in Subjects With Presbyopia
Latest Information Update: 12 May 2022
At a glance
- Drugs Lipoic acid choline ester (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 16 Mar 2020 Status changed from recruiting to completed.
- 27 Jun 2019 Planned End Date changed from 18 Oct 2019 to 4 Dec 2019.
- 27 Jun 2019 Planned primary completion date changed from 18 Oct 2019 to 31 Jul 2019.